Hikma launches Mitomycin for Injection, USP
London, 29 January 2019 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces that Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals Corp., has launched Mitomycin for Injection, USP, 20mg and 40mg.
Hikma’s Mitomycin for Injection, USP is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy.
According to IQVIA, US sales of Mitomycin for Injection were approximately $43 million in the 12 months ending November 2018.
Riad Mechlaoui, President of Injectables said, “We are excited to add Mitomycin for Injection to our oncology portfolio in the US, improving patients’ access to this important medicine. This demonstrates the successful execution of our strategy to expand our portfolio in key therapeutic areas.”
This new product introduction expands Hikma’s broad US offering of more than 90 injectable products and further solidifies our position as one of the top three suppliers of generic injectable products to US hospitals.